Pipeline and Commercial Insight: Migraine - Challenges Ahead for First-in-Class Developments by Datamonitor Now Available at ReportsandReports
After 4 years of steady growth, the migraine market across the seven major regions was valued at $4.6 billion in 2008.
Dallas, TX, August 13, 2010 --(PR.com)-- ReportsandReports Announce it Will Carry Pipeline and Commercial Insight: Migraine - Challenges ahead for first-in-class developments Market Research Report in its Store.
Browse the complete Report on: http://www.reportsandreports.com/market-reports/pipeline-and-commercial-insight-migraine-challenges-ahead-for-/
After 4 years of steady growth, the migraine market across the seven major regions was valued at $4.6 billion in 2008. However, following US patent expiries of both the acute migraine market leading brand, Imitrex (sumatriptan; GlaxoSmithKline), and leading prophylactic Topamax (topiramate; Johnson & Johnson), the market value plummeted by almost $1.5 billion from 2008 to $3.6 billion in 2009.
Scope
- Analysis of current migraine treatment approaches and drug recommendations, patient acquisition process and unmet medical needs.
- In depth analysis of historic (200509) and future (20102019) seven major market prescription sales dynamics.
- Review of the migraine drug pipeline dynamics, including detailed profiling of key late-stage products.
- Commercial and clinical assessment of key late-stage pipeline drugs, with key opinion leader comment and region-specific sales forecasts to 2019.
Highlights
In 2019, the seven major migraine market total is forecast to reach $2.8 billion. While high generic competition will continue to dictate the US market decline, proposed or enacted price reductions in the European countries will offset the uptake of new products and inhibit growth in this region.
Browse all Healthcare at http://www.reportsandreports.com/market-research/healthcare/
Browse all Datamonitor at http://www.reportsandreports.com/Publishers/datamonitor
Browse Latest Reports at: http://www.reportsandreports.com/LatestReport.aspx
Related Reports:
Pipeline and Commercial Insight: Insomnia - Future of innovative orexin drug class in doubt
http://www.reportsandreports.com/market-reports/pipeline-and-commercial-insight-insomnia-future-of-innovative-/
Pipeline and Commercial Insight: Allergic Rhinitis - Immunotherapy growth surpassed by generic erosion
http://www.reportsandreports.com/market-reports/pipeline-and-commercial-insight-allergic-rhinitis-immunotherap/
Commercial Insight: Antidiabetics in Australia - Reimbursement status shapes novel classes
http://www.reportsandreports.com/market-reports/commercial-insight-antidiabetics-in-australia-reimbursement-st/
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
http://www.reportsandreports.com/
http://reportsnreports.wordpress.com/
###
Browse the complete Report on: http://www.reportsandreports.com/market-reports/pipeline-and-commercial-insight-migraine-challenges-ahead-for-/
After 4 years of steady growth, the migraine market across the seven major regions was valued at $4.6 billion in 2008. However, following US patent expiries of both the acute migraine market leading brand, Imitrex (sumatriptan; GlaxoSmithKline), and leading prophylactic Topamax (topiramate; Johnson & Johnson), the market value plummeted by almost $1.5 billion from 2008 to $3.6 billion in 2009.
Scope
- Analysis of current migraine treatment approaches and drug recommendations, patient acquisition process and unmet medical needs.
- In depth analysis of historic (200509) and future (20102019) seven major market prescription sales dynamics.
- Review of the migraine drug pipeline dynamics, including detailed profiling of key late-stage products.
- Commercial and clinical assessment of key late-stage pipeline drugs, with key opinion leader comment and region-specific sales forecasts to 2019.
Highlights
In 2019, the seven major migraine market total is forecast to reach $2.8 billion. While high generic competition will continue to dictate the US market decline, proposed or enacted price reductions in the European countries will offset the uptake of new products and inhibit growth in this region.
Browse all Healthcare at http://www.reportsandreports.com/market-research/healthcare/
Browse all Datamonitor at http://www.reportsandreports.com/Publishers/datamonitor
Browse Latest Reports at: http://www.reportsandreports.com/LatestReport.aspx
Related Reports:
Pipeline and Commercial Insight: Insomnia - Future of innovative orexin drug class in doubt
http://www.reportsandreports.com/market-reports/pipeline-and-commercial-insight-insomnia-future-of-innovative-/
Pipeline and Commercial Insight: Allergic Rhinitis - Immunotherapy growth surpassed by generic erosion
http://www.reportsandreports.com/market-reports/pipeline-and-commercial-insight-allergic-rhinitis-immunotherap/
Commercial Insight: Antidiabetics in Australia - Reimbursement status shapes novel classes
http://www.reportsandreports.com/market-reports/commercial-insight-antidiabetics-in-australia-reimbursement-st/
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
http://www.reportsandreports.com/
http://reportsnreports.wordpress.com/
###
Contact
ReportsandReports
Akshata Patil
+1-888-989-8004
http://www.reportsandreports.com/
Akshata Patil
+1-888-989-8004
http://www.reportsandreports.com/
Contact
Categories